Ligilactobacillus salivarius
Ligilactobacillus salivarius (species-level entry, no specific strain designation) is an oral and intestinal lactic acid bacterium studied across several strains for immune modulation and respiratory health. A randomized controlled trial examined L. salivarius LS01 in children with asthma, and animal studies have examined long-term protection outcomes against Streptococcus pneumoniae in certain strains. An observational report examined immune and nutritional markers in elderly nursing home residents given another strain during the COVID-19 pandemic. Because the linked evidence spans multiple distinct strains, strain-specific conclusions cannot be drawn; the species has been studied in immune and respiratory contexts, but human evidence remains preliminary and strain-dependent. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 333 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 93 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
Strains of this species
7 strains of Ligilactobacillus salivarius in the index, with 110 linked papers between them.
Ligilactobacillus salivarius UCC118
Ligilactobacillus salivarius UCC118 is a well-studied gastrointestinal strain notable for its production of Abp118, a broad-spectrum bacteriocin (a ribosomally synthesized antimicrobial peptide), which has been studied i…
Ligilactobacillus salivarius CECT5713
Ligilactobacillus salivarius CECT5713 is a lactic acid bacterium originally isolated from human breast milk.
Ligilactobacillus salivarius LS01
Ligilactobacillus salivarius LS01 (also registered as DSM 22775) has been studied in the context of atopic dermatitis, a chronic inflammatory skin condition, in several randomized, placebo-controlled trials in adults and…
Ligilactobacillus salivarius LS-33
Ligilactobacillus salivarius LS-33 (previously classified within the Lactobacillus salivarius group) appears primarily in multi-strain research, making it difficult to isolate its individual contribution from the availab…
Ligilactobacillus salivarius PS2
Ligilactobacillus salivarius PS2 (formerly Lactobacillus salivarius PS2) has been studied specifically in the context of lactational mastitis, a breast infection that can occur in breastfeeding women.
Ligilactobacillus salivarius AP-32
Ligilactobacillus salivarius AP-32 (previously classified as Lactobacillus salivarius AP-32) is a strain that has been evaluated primarily in infant and animal research contexts.
Ligilactobacillus salivarius LS-ARS2
Ligilactobacillus salivarius LS-ARS2 is a lactic acid bacterium characterized by biofilm formation and antimicrobial compound production.
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
470 papers reference this strain in the probiotic database.
Discussion
Be the first to comment.
Sign in to join the discussion.
Citations
Selected papers that name this strain.
-
[1]
Source →Probiotic supplementation improves quality of life and modulates oestradiol in women with endometriosis: a randomised double-blind pilot trial· Figshare · 2026
-
[2]
PMID 41484513 →Probiotic-Containing Nanofiber-Based Dental Floss Suppresses Subgingival Red Complex Periopathogens: A Randomized Double-Blind Crossover Trial· Probiotics and Antimicrobial Proteins · 2026
-
[3]
PMID 40739452 →Correction: Assessing the Efficacy of Ligilactobacillus salivarius CLS0420 and Lacticaseibacillus paracasei CLPC0603 on Vaginal Well-Being in Healthy Women: A Pilot, Randomized, Double-Blind, Placebo-Controlled Trial· Probiotics and Antimicrobial Proteins · 2025
-
[4]
PMID 40507130 →Ligilactobacillus salivarius CECT5713 Increases Term Pregnancies in Women with Infertility of Unknown Origin: A Randomized, Triple-Blind, Placebo-Controlled Trial· Nutrients · 2025
-
[5]
PMID 38540885 →Understanding Ligilactobacillus salivarius from Probiotic Properties to Omics Technology: A Review· Foods · 2024
-
[6]
PMID 38955352 →Ligilactobacillus salivarius V4II-90 eradicates Group B Streptococcus colonisation during pregnancy: a randomised, double-blind, placebo-controlled trial· Beneficial Microbes · 2024
-
[7]
PMID 39023333 →Effect of tablets containing a paraprobiotic strain and the cranberry extract on caries incidence in preschool children: A randomized controlled trial· Dental and Medical Problems · 2024
-
[8]
PMID 37953676 →Ligilactobacillus salivarius CCFM 1266 modulates gut microbiota and GPR109a-mediated immune suppression to attenuate immune checkpoint blockade-induced colitis· Food & Function · 2023
-
[9]
PMID 36865781 →A randomized pilot trial assessing the reduction of gout episodes in hyperuricemic patients by oral administration of Ligilactobacillus salivarius CECT 30632, a strain with the ability to degrade purines· Frontiers in Microbiology · 2023
-
[10]
PMID 37007532 →Assessment of the safety and probiotic characteristics of Lactobacillus salivarius CGMCC20700 based on whole-genome sequencing and phenotypic analysis· Frontiers in Microbiology · 2023